The head of the Federal medical-biological Agency (FMBA) Veronika Skvortsova presented the results of preclinical studies of the drug “Mefloquine” for the treatment of coronavirus infection. It is reported by RIA Novosti.


As it turned out, the drug completely inhibits the cytopathic effect of the virus within 48 hours from the time of infection, but in a very small dose of two micrograms per milliliter.

If the drug is used to infection, then the virus is reduced by 50-75%, said Skvortsova, that may allow you to use it for prevention.

The head of the Agency said that on the basis of four leading centres of clinical research is “Mefloquine” in comparison with other antiviral drugs, and certain advantages are seen in patients of average weight.

According to her, by the end of the first week of admission, 70% of patients are guaranteed to get rid of the coronavirus, while in 26% it causes side effects.

Earlier, the Ministry of health updated guidelines for COVID-19.